--- title: "The performance of leading pharmaceutical companies continues to validate high prosperity, highlighting the undervalued allocation value of the pharmaceutical and biotechnology sector" type: "News" locale: "en" url: "https://longbridge.com/en/news/280285422.md" description: "As of March 24, the pharmaceutical sector has risen against the trend, with several companies such as KEYMED BIO-B and INSILICO showing significant gains. The industry is overall driven by dual engines of CXO pharmaceutical outsourcing services and ADC antibody-drug conjugates, with leading companies maintaining high performance and a stable policy environment. WuXi AppTec expects double-digit revenue growth by 2025, with ADC innovative drugs gradually entering the harvest period, increasing industry concentration, and deepening the competitive moat of leading enterprises. Investors may focus on ETFs in the biotechnology and innovative drug sectors" datetime: "2026-03-24T06:24:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280285422.md) - [en](https://longbridge.com/en/news/280285422.md) - [zh-HK](https://longbridge.com/zh-HK/news/280285422.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280285422.md) | [繁體中文](https://longbridge.com/zh-HK/news/280285422.md) # The performance of leading pharmaceutical companies continues to validate high prosperity, highlighting the undervalued allocation value of the pharmaceutical and biotechnology sector As of March 24th, 14:00, the pharmaceutical sector is rising against the trend, with **KEYMED BIO-B (02162.HK)**, **INSILICO (03696.HK)**, **VILITZ BIO-B (09887.HK)**, **KELUN-BIOTECH (06990.HK)**, and **CANFO BIO (09926.HK)** leading the gains. The **E Fund Hang Seng SCHK Innovative Drug ETF (159316)** rose by 2.46%, with the industry overall showing a dual-driven pattern of CXO pharmaceutical outsourcing services and ADC antibody-drug conjugates innovation drugs. The performance and orders of leading companies continue to reflect high prosperity, and the industry policy environment is becoming more stable, gradually revealing the allocation value of the sector. The performance of CXO leaders is steadily recovering, with leading company **WuXi AppTec (02359.HK)** achieving double-digit revenue growth in 2025. The TIDES business in peptides/oligonucleotides has doubled, becoming a core growth engine; the company has abundant orders on hand, with revenue growth guidance for 2026 reaching 18%-22%. As capacity utilization increases and the proportion of high-margin businesses rises, gross margins continue to improve, while the global supply chain position remains solid, and revenue in the U.S. market maintains rapid growth. ADC innovative drugs are gradually entering a harvest period, with core products steadily advancing in domestic commercialization, and expectations for volume growth increasing after being included in medical insurance. Overseas clinical data will be released successively by the end of 2026; the technology platform continues to be implemented and transformed, achieving multiple licensing collaborations with overseas pharmaceutical companies, with significant contributions from upfront payments and milestone revenues. The multi-target pipeline layout is complete, and combination therapy further opens up growth space. The CRDMO leader in bioconjugates has strong pipeline momentum, with orders on hand increasing by over 50% year-on-year. At the industry level, policy marginal stability is trending, with the normalization of innovative drug review and approval and medical insurance negotiations, continuously validating the commercialization capabilities of leading companies. The global industrial chain division of labor is deepening, with China's pharmaceutical outsourcing and innovative drug R&D global share continuously increasing, and industry concentration is rising, with the leading moat deepening due to advantages in technology, capacity, and customers. **To seize the high prosperity opportunities in the pharmaceutical sector, two core ETF targets can be focused on: in the biotechnology field, pay attention to the E Fund Hang Seng Biotechnology ETF (159105), and in the innovative drug field, focus on the E Fund Hang Seng SCHK Innovative Drug ETF (159316).** ### Related Stocks - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md) - [CAM HSBIOTECH (03069.HK)](https://longbridge.com/en/quote/03069.HK.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/en/quote/513700.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md) - [KEYMED BIO-B (02162.HK)](https://longbridge.com/en/quote/02162.HK.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/en/quote/513060.CN.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [China Southern CNI HK Connect Innovative Drug ETF (159297.CN)](https://longbridge.com/en/quote/159297.CN.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md) - [WuXi AppTec (603259.CN)](https://longbridge.com/en/quote/603259.CN.md) - [EFUND BIOPHAR ETF (03186.HK)](https://longbridge.com/en/quote/03186.HK.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md) - [GX CN BIOTECH (02820.HK)](https://longbridge.com/en/quote/02820.HK.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/en/quote/520500.CN.md) - [INSILICO (03696.HK)](https://longbridge.com/en/quote/03696.HK.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md) - [WUXI APPTEC (02359.HK)](https://longbridge.com/en/quote/02359.HK.md) - [CAM HSBIOTECH-R (83069.HK)](https://longbridge.com/en/quote/83069.HK.md) - [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/en/quote/562050.CN.md) - [WUXI BIO (02269.HK)](https://longbridge.com/en/quote/02269.HK.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/en/quote/159615.CN.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/en/quote/159570.CN.md) - [Harvest CSI Hong Kong Connect Innovative Drugs ETF (520970.CN)](https://longbridge.com/en/quote/520970.CN.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [WuXi Biologics (Cayman) Inc. (WXXWY.US)](https://longbridge.com/en/quote/WXXWY.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md) - [CCB Principal CSI Innovative Drugs Industry ETF (159835.CN)](https://longbridge.com/en/quote/159835.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) ## Related News & Research - [InSilico Expands AI-Driven CNS Collaboration With Tenacia in USD94.75 Million Deal](https://longbridge.com/en/news/280541264.md) - [TransThera Sciences Widens Annual Loss Amid Continued R&D Spend](https://longbridge.com/en/news/281187419.md) - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/en/news/281054154.md) - [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/en/news/281068292.md) - [Innovent Biologics posts FY profit RMB813.6 million](https://longbridge.com/en/news/280626112.md)